Last reviewed 2026-04-23 · How we verify

Concomitant Antibiotic Therapy

Concomitant antibiotic therapy works by simultaneously administering multiple antibiotics to target bacteria through different mechanisms, reducing resistance and improving treatment efficacy.

Concomitant antibiotic therapy works by simultaneously administering multiple antibiotics to target bacteria through different mechanisms, reducing resistance and improving treatment efficacy. Used for Serious bacterial infections (specific indication dependent on Phase 3 trial design).

At a glance

Mechanism of action

This approach combines antibiotics with distinct mechanisms of action (e.g., beta-lactams, fluoroquinolones, macrolides) to provide synergistic bacterial killing and minimize the development of antibiotic resistance. By attacking pathogens at multiple biochemical pathways simultaneously, concomitant therapy increases the likelihood of bacterial eradication and reduces treatment failure rates. This strategy is particularly valuable in serious infections where monotherapy may be insufficient or resistance is a concern.

Approved indications

• Serious bacterial infections (specific indication dependent on Phase 3 trial design)

Common side effects

• Gastrointestinal disturbances (nausea, diarrhea)
• Allergic reactions
• Drug-drug interactions
• Photosensitivity (if fluoroquinolone-containing)

Key clinical trials

• MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
• A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
• A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (PHASE2)
• Point of Care Respiratory Pathogen Testing for Antibiotic Stewardship in Primary Care (NA)
• Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis (PHASE1)
• Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin (PHASE2, PHASE3)
• Therapeutic Monitoring of Beta-lactams in Critically Ill Patients With Sepsis (NA)
• In Vivo Antibiotics Removal During Hemoadsorption Cartridges and Continuous Renal Replacement Therapy in the Intensive Care Unit

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.